Novel ULK Inhibitor Considered Safe for Solid Tumors Harboring RAS or RAF Mutations
September 11th 2022DCC-3116 demonstrated safety and tolerability across various dose levels in patients with solid tumors harboring a RAS or RAF mutation, according to findings from a phase 1/2 trial presented at the 2022 ESMO Congress.
CLDN6 CAR T-Cell Therapy Elicits Clinical Activity in Relapsed/Refractory Advanced Solid Tumors
September 9th 2022The investigational carcinoembryonic antigen claudin 6–directed CAR T-cell therapy BNT211-01 displayed clinical activity in combination with a CLDN6-encoding mRNA vaccine in patients with CLDN6-positive relapsed/refractory advanced solid tumors.
Daratumumab Plus Lenalidomide/Dexamethasone Prolong OS When Administered Long-Term in Myeloma
August 26th 2022Patients with treatment-naive myeloma treated with humanized IgGx CD38-targeted monoclonal antibody daratumumab in combination with lenalidomide and dexamethasone for at least 18 months had a overall survival benefit in the phase 3 MAIA study.
GVHD Prophylaxis After TBI Decreases Rates of GVHD in Hematologic Malignancies
April 25th 2022Total body irradiation (TBI) regimen and myeloablative transplantation followed by a graft-versus-host disease (GVHD) prophylaxis regimen resulted in a low occurrence of GVHD in adult and pediatric patients with hematologic malignancies
Roughly 15% of Nonclonal Recurrent DCIS Cases May Be Undertreated, Research Suggests
April 10th 2022According to Tanjina Kader, PhD, 12% of patients in the cohort who developed new, independent primary tumors raised the question of whether using these genetic biomarkers for prediction of recurrence is a good idea.
COVID-19 Continues On, Vaccinations Are Strongly Urged for All Patients With Cancer
December 20th 2021In light of the continued risks of COVID-19, especially for immunocompromised patients and those with cancer, physicians and guidelines have recommended vaccination including booster shots as soon as possible for all patients with cancer.
Direct and Multifaceted LSAM-DTX Treatment May Be Safe and Effective in NMIBC
September 13th 2021Administration of direct intramural injection and intravesical instillations of large surface area microparticle docetaxel may be safe and effective in high-risk non-muscle invasive bladder cancer using a particular technique.